Tesamorelin never touches a fat cell to start with. It binds receptors on the pituitary, and the visceral fat reduction it is known for happens two steps later, through growth hormone and then IGF-1. That distance is why the effect builds over months and reverses when the drug stops.
Tesamorelin does one thing directly: it binds GHRH receptors on the pituitary and prompts release of the growth hormone the body already produces. Everything people associate with it, the reduction in visceral abdominal fat most of all, happens downstream through GH and then IGF-1. It is FDA-approved for reducing excess abdominal fat in HIV-infected adult patients with lipodystrophy [1], and that is the only thing it is approved to do.
- Tesamorelin is a stabilized GHRH analog. It stimulates the pituitary rather than supplying GH [1]
- The GH it releases raises IGF-1, which rose 81.0% over 26 weeks in the NEJM trial [2]
- Its documented effect is reduction of visceral adipose tissue, 15.2% at 26 weeks versus placebo [2]
- It is approved for one indication only: HIV-associated lipodystrophy in adults [1]
- Visceral fat reaccumulates when treatment stops [4], so it manages the condition rather than resolving it
The Mechanism, Step by Step
Tesamorelin is a synthetic analog built on the full 44-amino-acid sequence of human GHRH with an N-terminal modification that keeps it intact in circulation [1]. What follows an injection is a sequence, not a single event.
- Tesamorelin binds GHRH receptors on somatotroph cells in the anterior pituitary
- Those cells release stored growth hormone in a pulse
- GH reaches the liver, which produces IGF-1, the downstream mediator of most effects
- GH and IGF-1 together promote lipolysis, drawing down visceral and abdominal fat over time
The second step is the important one. Because the pituitary does the releasing, somatostatin feedback stays in place and the axis is not bypassed the way it is with injected growth hormone. That is a self-limiting design, and it is also why the effect has a ceiling rather than climbing indefinitely with dose.
Why the Effect Lands on Visceral Fat
Visceral adipose tissue is unusually responsive to growth hormone signaling, which is why tesamorelin was developed and studied specifically for it. The trial data is consistent across large programs.
| Trial | Population | Visceral fat result |
|---|---|---|
| [NEJM 2007, 412 patients](https://pubmed.ncbi.nlm.nih.gov/18057338/) [2] | HIV lipodystrophy | 15.2% reduction at 26 weeks vs 5.0% increase on placebo |
| [Pooled phase 3, 806 patients](https://pubmed.ncbi.nlm.nih.gov/20554713/) [3] | HIV lipodystrophy | 15.4% treatment effect at 26 weeks, 17.5% at 52 weeks |
| [JAIDS 2010, 404 patients](https://pubmed.ncbi.nlm.nih.gov/20101189/) [4] | HIV lipodystrophy | 10.9% reduction at 6 months, reaccumulation after stopping |
The IGF-1 rise tracks the fat change and is the biomarker used to confirm the axis is responding. In the 412-patient trial IGF-1 rose 81.0% with tesamorelin versus a 5.0% decrease on placebo [2]. That is a large, measurable signal, and it is why IGF-1 monitoring is part of the label.
What Tesamorelin Is Approved to Do
The approved indication is narrow and specific. Tesamorelin, marketed as EGRIFTA, is indicated for reducing excess abdominal fat in HIV-infected adult patients with lipodystrophy [1]. It is not approved for the general population, and the label does not support use for cosmetic fat loss or aging.
Visceral fat returned after tesamorelin was discontinued [4]. GHRH-analog therapy suppresses a process rather than permanently resetting it, which matters for anyone imagining a short fixed course.
What Tesamorelin Does Not Do
- It does not deliver growth hormone. It prompts release of the hormone you already produce [1]
- It is not approved for general weight loss, anti-aging, or bodybuilding
- It does not reduce subcutaneous fat the way it reduces visceral fat, and it is not a body-contouring drug
- It does not produce permanent change; visceral fat reaccumulates after stopping [4]
- It is not the same molecule as compounded sermorelin, which is a shorter GHRH(1-29) fragment [7] used off-label for age-related decline
Why Tesamorelin Lasts Longer Than Sermorelin
Native GHRH is cleared within minutes by the enzyme dipeptidyl peptidase-4. Tesamorelin's N-terminal modification confers resistance to degradation by dipeptidyl peptidase-4 [6], which extends its functional half-life and lets a once-daily dose sustain the GH signal. Sermorelin, the shorter fragment, clears far faster and is dosed nightly at bedtime for that reason. The glucose question that follows any GH-axis therapy has been reassuring over a full course, with reviews describing a modest early rise in HbA1c that was no longer evident by 52 weeks [5].
Tesamorelin is approved only for HIV-associated lipodystrophy and is priced as a specialty product. For age-related GH decline, the GHRH analog that telehealth platforms dispense is compounded sermorelin, and the honest starting point is a baseline IGF-1. SystemLabs includes baseline IGF-1 testing before prescribing, so you have a real number to measure the 90-day response against.
Bottom Line
Frequently Asked Questions
What does tesamorelin do in the body?
It binds GHRH receptors on the anterior pituitary and stimulates release of the growth hormone the body already produces [1]. That GH raises IGF-1, and GH and IGF-1 together promote breakdown of visceral and abdominal fat. Tesamorelin does not act on fat cells directly, which is why its effect develops over months rather than days.
What does tesamorelin do for belly fat?
It reduces visceral abdominal fat specifically. In a 412-patient trial, visceral adipose tissue fell 15.2% at 26 weeks versus a 5.0% increase on placebo [2], and a pooled analysis of 806 patients found a 15.4% treatment effect at 26 weeks extending to 17.5% at 52 weeks [3]. It targets visceral fat rather than the subcutaneous fat under the skin, and the visceral fat returns after treatment stops [4].
Does tesamorelin actually work?
Within its studied population, yes, with large randomized placebo-controlled trials behind it. Visceral fat reductions of roughly 11 to 17% and an 81.0% rise in IGF-1 were documented in HIV-infected adults with lipodystrophy [2][3][4]. Those results apply to that population; tesamorelin has not been studied for general weight loss or anti-aging.
What is tesamorelin approved for?
One indication only: reducing excess abdominal fat in HIV-infected adult patients with lipodystrophy, under the brand EGRIFTA [1]. It is not FDA-approved for general fat loss, aging, or athletic performance. Any use outside HIV-associated lipodystrophy is off-label.
Does tesamorelin build muscle?
It is not a muscle-building drug and was not studied for that. Its documented effect is reduction of visceral fat through the GH and IGF-1 axis [2]. While GH and IGF-1 influence lean tissue generally, tesamorelin's trials measured abdominal fat, not muscle mass or strength, so any muscle claim is an extrapolation rather than a finding.
Is tesamorelin the same as sermorelin?
No. Both are GHRH analogs that stimulate the pituitary, but tesamorelin is the stabilized 44-amino-acid molecule that resists DPP-4 breakdown [6], while sermorelin is the shorter GHRH(1-29) fragment [7] that clears in minutes. Tesamorelin is FDA-approved for HIV lipodystrophy; sermorelin is compounded and used off-label for age-related GH decline.
References
- EGRIFTA SV (tesamorelin) for injection, for subcutaneous use: full prescribing information DailyMed, U.S. National Library of Medicine, 2010. Initial U.S. Approval: 2010. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224
- Metabolic effects of a growth hormone-releasing factor in patients with HIV New England Journal of Medicine, 2007. PMID: 18057338. https://pubmed.ncbi.nlm.nih.gov/18057338/
- Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data Journal of Clinical Endocrinology & Metabolism, 2010. PMID: 20554713. https://pubmed.ncbi.nlm.nih.gov/20554713/
- Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension Journal of Acquired Immune Deficiency Syndromes, 2010. PMID: 20101189. https://pubmed.ncbi.nlm.nih.gov/20101189/
- Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies Growth Hormone & IGF Research, 2015. PMID: 25555516. https://pubmed.ncbi.nlm.nih.gov/25555516/
- Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy HIV/AIDS (Auckland), 2011. PMID: 22096409. https://pubmed.ncbi.nlm.nih.gov/22096409/
- Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency BioDrugs, 1999. PMID: 18031173. https://pubmed.ncbi.nlm.nih.gov/18031173/
